

July 3, 2026

To whom it may concern

Company Name: Innovacell Inc.
Representative: Representative Director Co-CEO
Colin Novick
Representative: Representative Director Co-CEO
Jason Sieger
(Code No.: 504A, Growth Market of the Tokyo Stock Exchange)
Point of Contact: Director CFO Yasushi Hosono
(<https://innovacell.com/contact/?lang=en>)

Announcement Regarding a Video Elaborating on Completion of FDA IND Review and Approval to Include U.S. Sites and Patients in the ICEF15 Multi-Regional Phase III Fidelia Trial

We hereby announce that we have released a video in which our Co-CEOs (Colin Novick and Jason Sieger) provided in-depth explanation of the news release titled “Announcement Regarding Completion of FDA IND Review and Approval to Include U.S. Sites and Patients in the ICEF15 Multi-Regional Phase III Fidelia Trial,” which we disclosed yesterday (July 2, 2026). We hope this video will serve as a useful reference for gaining a deeper understanding of the progress of Innovacell Group’s business operations.

1. Release date : July 3, 2026
2. Video URL : <https://innovacell.com/20260703-icef15/?lang=en>

■ About Innovacell Inc. (<https://innovacell.com/?lang=en>)

Innovacell Inc. traces its origins to a regenerative medicine company spun out from the Medical University of Innsbruck in Austria. The Company was established in Japan in 2021 as the parent company of that Austrian business (now Innovacell GmbH).

Innovacell Group aims to improve patients’ health and quality of life (QOL) through the development and commercialization of cell therapies and regenerative medicine. It is currently focused on developing and commercializing regenerative medicine products for the treatment of urge and passive fecal incontinence as well as stress urinary incontinence.

ICEF15, the most advanced of the Group’s pipeline products, aims to treat urge fecal incontinence by regenerating muscle tissue via the local administration of a patient’s own skeletal muscle-derived cells (myoblasts). ICEF15 is currently undergoing a multi-regional Phase III clinical trial in 11 European countries and Japan.

To date, Innovacell GmbH has completed multiple clinical trials in Europe, including Phase IIb trials for ICEF15 (urge fecal incontinence) and ICES13 (stress urinary incontinence).

End